Hipertensión pulmonar primaria: Actualización terapéutica

• Autores: Esther López Suñé, Dolors Soy Muner, Carlos Codina Jané, Josep Ribas Sala
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 7, Nº. 1, 2005, págs. 25-39
• Idioma: español
• Títulos paralelos:
  • Therapeutic update of a disease with difficult control: Primary pulmonary hypertension
• Texto completo no disponible (Saber más ...)
• Resumen

  • Primary pulmonary hypertension is a pathology of unknown origin. The growing development of new therapeutic options allows for the increase in the quality and the life expectancy of the affected patients. 25 to 30% of patients respond to the treatment with calcium channel blockers in high doses. The non-responsive ones can be treated with prostanoids (epoprostenol, iloprost, treprostinil and beraprost) or with endothelin antagonists (bosentan and sitaxsentan). The first ones are drugs with a half-life of short elimination, that must be administrated in a continuous infusion or in several daily administrations. The endothelin antagonists present half-lives of more prolonged elimination, which allows them to be administrated by oral pathway. Other therapeutic options include the use of phosphodiesterase inhibitors, like sildenafil. Additional studies are necessary to establish the long-term efficiency and safety of these drugs and to determine whether the combined therapy with more than one of them may result beneficial